10X GENOMICS INC CLASS A (TXG) — insider trading
Health Care · NASDAQ
10X GENOMICS INC CLASS A (TXG) has 47 reported SEC Form 4 insider transactions in our data, including 39 open-market sales among the most recent 47 (latest 2026-09-22).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-09-22 | SULIMAN SHEHNAAZ | Director | Open-market sale | 1,222 | $82.28 | $100.5K | Form 4 |
| 2026-09-22 | SULIMAN SHEHNAAZ | Director | Open-market sale | 2,270 | $81.67 | $185.4K | Form 4 |
| 2026-09-22 | SULIMAN SHEHNAAZ | Director | Open-market sale | 1,325 | $80.82 | $107.1K | Form 4 |
| 2026-09-22 | SULIMAN SHEHNAAZ | Director | Open-market sale | 614 | $79.51 | $48.8K | Form 4 |
| 2026-09-22 | SULIMAN SHEHNAAZ | Director | Open-market sale | 292 | $78.20 | $22.8K | Form 4 |
| 2026-09-22 | Saxonov Serge | Director, Officer (Chief Executive Officer) | Open-market sale | 2,800 | $82.37 | $230.6K | Form 4 |
| 2026-09-22 | Saxonov Serge | Director, Officer (Chief Executive Officer) | Open-market sale | 9,900 | $81.83 | $810.1K | Form 4 |
| 2026-09-22 | Saxonov Serge | Director, Officer (Chief Executive Officer) | Open-market sale | 9,300 | $80.90 | $752.4K | Form 4 |
| 2026-09-22 | Saxonov Serge | Director, Officer (Chief Executive Officer) | Open-market sale | 2,000 | $79.62 | $159.2K | Form 4 |
| 2026-09-22 | Saxonov Serge | Director, Officer (Chief Executive Officer) | Open-market sale | 1,000 | $78.23 | $78.2K | Form 4 |
| 2026-09-09 | Taich Adam | Officer (Chief Financial Officer) | Open-market sale | 13,754 | $65.26 | $897.6K | Form 4 |
| 2026-09-09 | Taich Adam | Officer (Chief Financial Officer) | Open-market sale | 31,428 | $64.31 | $2.02M | Form 4 |
| 2026-09-09 | Taich Adam | Officer (Chief Financial Officer) | Open-market sale | 1,206 | $63.68 | $76.8K | Form 4 |
| 2026-09-03 | STUELPNAGEL JOHN R | Director | Open-market sale | 6,174 | $62.61 | $386.5K | Form 4 |
| 2026-09-03 | STUELPNAGEL JOHN R | Director | Open-market sale | 6,814 | $62.11 | $423.2K | Form 4 |
| 2026-09-03 | STUELPNAGEL JOHN R | Director | Open-market sale | 7,012 | $60.66 | $425.3K | Form 4 |
| 2026-09-01 | Saxonov Serge | Director, Officer (Chief Executive Officer) | Bona fide gift | 100 | — | $0 | Form 4 |
| 2026-08-26 | Saxonov Serge | Director, Officer (Chief Executive Officer) | Open-market sale | 492 | $64.75 | $31.9K | Form 4 |
| 2026-08-26 | Saxonov Serge | Director, Officer (Chief Executive Officer) | Open-market sale | 6,494 | $63.98 | $415.5K | Form 4 |
| 2026-08-26 | Saxonov Serge | Director, Officer (Chief Executive Officer) | Open-market sale | 3,500 | $63.02 | $220.6K | Form 4 |
| 2026-08-24 | Saxonov Serge | Director, Officer (Chief Executive Officer) | Open-market sale | 18,545 | $63.02 | $1.17M | Form 4 |
| 2026-08-24 | Taich Adam | Officer (Chief Financial Officer) | Open-market sale | 17,166 | $63.02 | $1.08M | Form 4 |
| 2026-08-24 | Hindson Benjamin J. | Director, Officer (See Remarks) | Open-market sale | 13,818 | $63.02 | $870.9K | Form 4 |
| 2026-08-24 | SULIMAN SHEHNAAZ | Director | Open-market sale | 1,646 | $63.97 | $105.3K | Form 4 |
| 2026-08-24 | SULIMAN SHEHNAAZ | Director | Open-market sale | 561 | $62.73 | $35.2K | Form 4 |
| 2026-08-20 | Saxonov Serge | Director, Officer (Chief Executive Officer) | Bona fide gift | 4,000 | — | $0 | Form 4 |
| 2026-08-14 | Teichmann Sarah A. | Director | Open-market sale | 2,273 | $57.15 | $129.9K | Form 4 |
| 2026-08-13 | Teichmann Sarah A. | Director | Open-market sale | 5,278 | $57.29 | $302.4K | Form 4 |
| 2026-08-11 | STUELPNAGEL JOHN R | Director | Open-market sale | 3,000 | $58.73 | $176.2K | Form 4 |
| 2026-08-11 | STUELPNAGEL JOHN R | Director | Open-market sale | 17,000 | $57.58 | $978.9K | Form 4 |
| 2026-06-22 | Saxonov Serge | Director, Officer (Chief Executive Officer) | Open-market sale | 1,661 | $36.16 | $60.1K | Form 4 |
| 2026-06-22 | Saxonov Serge | Director, Officer (Chief Executive Officer) | Open-market sale | 9,821 | $35.32 | $346.8K | Form 4 |
| 2026-06-22 | Saxonov Serge | Director, Officer (Chief Executive Officer) | Open-market sale | 9,991 | $34.28 | $342.5K | Form 4 |
| 2026-06-22 | Saxonov Serge | Director, Officer (Chief Executive Officer) | Open-market sale | 8,527 | $33.29 | $283.9K | Form 4 |
| 2026-06-16 | SULIMAN SHEHNAAZ | Director | Open-market sale | 364 | $33.27 | $12.1K | Form 4 |
| 2026-06-16 | SULIMAN SHEHNAAZ | Director | Open-market sale | 5,359 | $32.59 | $174.6K | Form 4 |
| 2026-06-04 | Kosaraju Sridhar | Director | Grant / award / vesting | 8,829 | — | $0 | Form 4 |
| 2026-06-04 | MATEO ALAN | Director | Grant / award / vesting | 8,829 | — | $0 | Form 4 |
| 2026-06-04 | Popovits Kimberly J | Director | Grant / award / vesting | 8,829 | — | $0 | Form 4 |
| 2026-06-04 | STUELPNAGEL JOHN R | Director | Grant / award / vesting | 8,829 | — | $0 | Form 4 |
| 2026-06-04 | SULIMAN SHEHNAAZ | Director | Grant / award / vesting | 8,829 | — | $0 | Form 4 |
| 2026-06-04 | Teichmann Sarah A. | Director | Grant / award / vesting | 8,829 | — | $0 | Form 4 |
| 2026-05-26 | Saxonov Serge | Director, Officer (Chief Executive Officer) | Open-market sale | 10,718 | $24.71 | $264.8K | Form 4 |
| 2026-05-22 | Taich Adam | Officer (Chief Financial Officer) | Open-market sale | 15,098 | $24.44 | $369.0K | Form 4 |
| 2026-05-22 | Hindson Benjamin J. | Director, Officer (See Remarks) | Open-market sale | 11,595 | $24.44 | $283.4K | Form 4 |
| 2026-05-22 | Saxonov Serge | Director, Officer (Chief Executive Officer) | Open-market sale | 18,175 | $24.44 | $444.2K | Form 4 |
| 2026-04-14 | Saxonov Serge | Director, Officer (Chief Executive Officer) | Open-market sale | 5,000 | $24.56 | $122.8K | Form 4 |
Ask the chat about TXG's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: 10X GENOMICS INC CLASS A (TXG).
Last updated 2026-09-22 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.